News

TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.

Boston Scientific (NYSE: BSX) has initiated multiple worldwide product recalls, including a Class I recall of its ENROUTE Transcarotid Neuroprotection System due to risks of arterial sheath tip separation. The company has also begun Class II recalls of certain OverStitch Suture Cinch endoscopic devices, citing deployment and suture cutting failures. These recalls affect widely distributed products and introduce added operational, regulatory and reputational pressures for Boston Scientific in...

Boston Scientific stock has had a steep year, with a sharp share price decline set against valuation checks that point to a potentially cheap entry point based on intrinsic value and market multiples. The stock now screens as undervalued on both a Discounted Cash Flow (DCF) view and on broader valuation metrics, which raises questions about how much of the recent operational setbacks the market has already priced in. Over the past 12 months, Boston Scientific shares have fallen about 55%,...

Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.

Boston Scientific has gotten torched over the last six months - since March 2026, its stock price has dropped 36.9% to $48.10 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.

Despite Boston Scientific’s weak performance relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock’s prospects

This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.

AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.

The Standard & Poor's 500 index edged up 0.5% this week amid stronger-than-expected quarterly report

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The attack has affected the company’s ability to manufacture products and to process and ship customers’ orders, and there is still no timeline for restoration.

With Amulet 360, Abbott aims to capture share from Boston Scientific in the market for devices that seal the heart’s left atrial appendage to lower stroke risk.

AU, APTV and BSX have been added to the Zacks Rank #5 (Strong Sell) List on August 28th, 2026.

U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% gain over the past six months, beating the S&P 500 by 13.3 percentage points.

ISRG's record cash flow is fueling R&D, manufacturing expansion and over 100 da Vinci 5 updates, strengthening its innovation edge.

Alabama’s attorney general wants answers after OpenAI models went rogue during a test run and hacked a real-world company. The state this week subpoenaed OpenAI and CEO Sam Altman, looking for details about the incident as well as every employee involved, plus those who raised safety concerns. On Wednesday, the company released a lengthy report that addressed some, but not all, of the issues Alabama raised.

The cyberattack on Boston’s IT systems was identified on 25 August and has resulted in a global disruption to the company’s operations.

Boston Scientific (NYSE: BSX) reports a major cyberattack that is disrupting global operations and access to key IT systems. The company says the incident is impairing its ability to process customer orders worldwide and is still ongoing. Boston Scientific has activated its incident response protocol and is working to restore affected systems. Consider broadening your watchlist to other healthcare and medical technology stocks through 40 healthcare AI stocks. NYSE:BSX 1-Year Stock Price...

On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.

For long-suffering owners of Boston Scientific, here’s how to get paid a meaningful cash income now, yours to keep no matter what, in exchange for capping your gains at a higher price.

Healthcare stocks fell late Wednesday afternoon, with the NYSE Healthcare Index shedding 1% and the

Boston Scientific shares lost ground Wednesday after the company disclosed a cyberattack that caused global disruptions to its operations.

The company won't say if medical devices are affected or if any customer data was exfiltrated.

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the

The medical device specialist was the victim of a cyberattack.

Shares of medical-device maker Boston Scientific are down 4.5% Wednesday on concerns that a cyber-attack against the company could hurt near-term revenue. The incident, which Boston Scientific said it detected Tuesday, caused a network outage and disruption to operations, including the ability to process and ship orders, a spokeswoman said. Evercore ISI analysts noted that a similar cyberattack against medical-device maker Stryker in March took about three weeks for the company to recover from.

All three major US stock indexes were down slightly in late-morning trading Wednesday, as market par